Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

Animal models of antiretroviral prophylaxis for HIV prevention.

García-Lerma JG, Heneine W.

Curr Opin HIV AIDS. 2012 Nov;7(6):505-13. doi: 10.1097/COH.0b013e328358e484. Review.

PMID:
22964889
2.

Nondaily preexposure prophylaxis for HIV prevention.

Anderson PL, García-Lerma JG, Heneine W.

Curr Opin HIV AIDS. 2016 Jan;11(1):94-101. doi: 10.1097/COH.0000000000000213. Review.

3.

Considerations regarding antiretroviral chemoprophylaxis in MSM.

Poynten IM, Zablotska I, Grulich AE.

Curr Opin HIV AIDS. 2012 Nov;7(6):549-56. doi: 10.1097/COH.0b013e3283582c71. Review.

PMID:
22918448
4.

Oral pre-exposure prophylaxis for HIV prevention.

García-Lerma JG, Paxton L, Kilmarx PH, Heneine W.

Trends Pharmacol Sci. 2010 Feb;31(2):74-81. doi: 10.1016/j.tips.2009.10.009. Epub 2009 Dec 4. Review.

PMID:
19963288
5.

Repeated Vaginal SHIV Challenges in Macaques Receiving Oral or Topical Preexposure Prophylaxis Induce Virus-Specific T-Cell Responses.

Tsegaye TS, Butler K, Luo W, Radzio J, Srinivasan P, Sharma S, Aubert RD, Hanson DL, Dobard C, Garcia-Lerma JG, Heneine W, McNicholl JM, Kersh EN.

J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):385-94. doi: 10.1097/QAI.0000000000000642.

6.

A polyvalent Clade B virus-like particle HIV vaccine combined with partially protective oral preexposure prophylaxis prevents simian-human immunodeficiency virus Infection in macaques and primes for virus-amplified immunity.

Ross TM, Pereira LE, Luckay A, McNicholl JM, García-Lerma JG, Heneine W, Eugene HS, Pierce-Paul BR, Zhang J, Hendry RM, Smith JM.

AIDS Res Hum Retroviruses. 2014 Nov;30(11):1072-81. doi: 10.1089/AID.2014.0030. Epub 2014 Jul 29.

7.

Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges.

Subbarao S, Otten RA, Ramos A, Kim C, Jackson E, Monsour M, Adams DR, Bashirian S, Johnson J, Soriano V, Rendon A, Hudgens MG, Butera S, Janssen R, Paxton L, Greenberg AE, Folks TM.

J Infect Dis. 2006 Oct 1;194(7):904-11. Epub 2006 Aug 29.

PMID:
16960777
8.

Prophylactic efficacy of oral emtricitabine and tenofovir disoproxil fumarate combination therapy against a tenofovir-resistant simian/human immunodeficiency virus containing the K65R mutation in macaques.

Cong ME, Mitchell J, Sweeney E, Bachman S, Hanson DL, Heneine W, García-Lerma JG.

J Infect Dis. 2013 Aug 1;208(3):463-7. doi: 10.1093/infdis/jit189. Epub 2013 Apr 30.

9.

Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen.

Radzio J, Aung W, Holder A, Martin A, Sweeney E, Mitchell J, Bachman S, Pau CP, Heneine W, García-Lerma JG.

PLoS One. 2012;7(12):e50632. doi: 10.1371/journal.pone.0050632. Epub 2012 Dec 4.

10.

Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?

Parikh UM, Mellors JW.

Curr Opin HIV AIDS. 2016 Jan;11(1):49-55. doi: 10.1097/COH.0000000000000209. Review.

11.

Limited SHIV env diversification in macaques failing oral antiretroviral pre-exposure prophylaxis.

Zheng Q, Ruone S, Switzer WM, Heneine W, García-Lerma JG.

Retrovirology. 2012 May 9;9:40. doi: 10.1186/1742-4690-9-40.

12.

Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir.

García-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, Masciotra S, Luo W, Kim C, Adams DR, Monsour M, Lipscomb J, Johnson JA, Delinsky D, Schinazi RF, Janssen R, Folks TM, Heneine W.

PLoS Med. 2008 Feb;5(2):e28. doi: 10.1371/journal.pmed.0050028.

13.

Pre-exposure chemoprophylaxis of HIV infection: quo vadis?

Clercq ED.

Biochem Pharmacol. 2012 Mar 1;83(5):567-73. doi: 10.1016/j.bcp.2011.10.016. Epub 2011 Oct 29.

PMID:
22067069
14.

Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.

Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, Cohen MS, Kashuba AD.

Sci Transl Med. 2011 Dec 7;3(112):112re4. doi: 10.1126/scitranslmed.3003174.

15.

Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.

García-Lerma JG, Aung W, Cong ME, Zheng Q, Youngpairoj AS, Mitchell J, Holder A, Martin A, Kuklenyik S, Luo W, Lin CY, Hanson DL, Kersh E, Pau CP, Ray AS, Rooney JF, Lee WA, Heneine W.

J Virol. 2011 Jul;85(13):6610-7. doi: 10.1128/JVI.00311-11. Epub 2011 Apr 27.

16.

Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.

Denton PW, Estes JD, Sun Z, Othieno FA, Wei BL, Wege AK, Powell DA, Payne D, Haase AT, Garcia JV.

PLoS Med. 2008 Jan 15;5(1):e16. doi: 10.1371/journal.pmed.0050016.

18.

Antiretroviral Drug Activity in Macaques Infected during Pre-Exposure Prophylaxis Has a Transient Effect on Cell-Associated SHIV DNA Reservoirs.

Cong ME, Pau CP, Heneine W, García-Lerma JG.

PLoS One. 2016 Nov 2;11(11):e0164821. doi: 10.1371/journal.pone.0164821. eCollection 2016.

19.

Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine.

Parikh UM, Dobard C, Sharma S, Cong ME, Jia H, Martin A, Pau CP, Hanson DL, Guenthner P, Smith J, Kersh E, Garcia-Lerma JG, Novembre FJ, Otten R, Folks T, Heneine W.

J Virol. 2009 Oct;83(20):10358-65. doi: 10.1128/JVI.01073-09. Epub 2009 Aug 5.

20.

Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection.

García-Lerma JG, Cong ME, Mitchell J, Youngpairoj AS, Zheng Q, Masciotra S, Martin A, Kuklenyik Z, Holder A, Lipscomb J, Pau CP, Barr JR, Hanson DL, Otten R, Paxton L, Folks TM, Heneine W.

Sci Transl Med. 2010 Jan 13;2(14):14ra4. doi: 10.1126/scitranslmed.3000391.

Supplemental Content

Support Center